Replimune develops oncolytic immunotherapies, treatments built on engineered viruses that target skin cancers. It last closed at $19.07 on Nov 20, down 0.83% on the day. The next earnings report for REPL is expected around Tue, Feb 2, 2027. For the quarter ended Sep 2026, REPL reported EPS of -$0.54. Over its last 8 reports the stock moved an average of 5.8% the session after earnings. Over the last 12 months REPL insiders bought $0 of stock on the open market and sold $4.1M, according to SEC Form 4 filings.
AI Auto Pilots
Is REPL in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold REPL.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on REPLStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
REPL · as of the Nov 20 close · updated each morning
Uptrend
The stock sits between its 20 and 50 day averages. It is 46% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 54). The nearest support is the Pivot S1 at $18.67, and the nearest resistance the Pivot at $19.09.
Short trendBullish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityNormal, 6.7%/day
Key levels
$23.5452 week high+23.4%
$23.54Swing high (Nov 11)+23.4%
$19.48Pivot R1+2.1%
$19.4720 day average+2.1%
$19.09Pivot+0.1%
$19.07Last close
$18.67Pivot S1−2.1%
$15.3450 day average−19.6%
$14.90Swing low (Aug 31)−21.9%
$13.95100 day average−26.8%
$10.32200 day average−45.9%
$1.5052 week low−92.1%
Indicators
RSI (14)
54.26
Middle of its range
Neutral
MACD
1.53
Below its signal line
Bearish
Stochastic
26.8
Middle of its range
Neutral
ADX (14)
36.2
Trending up
Williams %R
-92.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-7.6
Oversold below −100, overbought above 100
Neutral
Rate of change
−11.8%
Change over 10 sessions
Bearish
ATR (14)
$1.27
Typical daily range, 6.7% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
Uptrend, nearing overbought
Short trendBullish
Long trendBullish
MomentumStrong
StretchNear overbought
VolatilityNormal, 13.9%/day
Key levels
$23.5452 week high+23.4%
$23.54Swing high (Nov 11)+23.4%
$19.48Pivot R1+2.1%
$19.4720 day average+2.1%
$19.09Pivot+0.1%
$19.07Last close
$18.67Pivot S1−2.1%
$15.3450 day average−19.6%
$14.90Swing low (Aug 31)−21.9%
$13.95100 day average−26.8%
$10.32200 day average−45.9%
$1.5052 week low−92.1%
Indicators
RSI (14)
63.76
Strong, overbought above 70
Neutral
MACD
2.54
Above its signal line
Bullish
Stochastic
83.3
Near the top of its range
Overbought
ADX (14)
19.0
No clear trend
Williams %R
-34.7
Oversold below −80, overbought above −20
Neutral
CCI (20)
152.5
Oversold below −100, overbought above 100
Overbought
Rate of change
+47.6%
Change over 10 sessions
Bullish
ATR (14)
$2.64
Typical daily range, 13.8% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for REPL
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how REPL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow REPL usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for REPLHow many large options trades hit REPL, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in REPL in the last 90 days.
From SEC Form 4 filings by REPL's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether REPL is in one of them and how their past REPL trades turned out.
Replimune is a biotechnology company based in Woburn, Massachusetts, that develops oncolytic immunotherapies for cancer. These treatments use an engineered herpes simplex virus to kill tumor cells directly and to stimulate the immune system against the cancer. Its lead candidate, RP1, is being studied mainly in advanced melanoma and other skin cancers, with patients as the intended users. The company's products are still in clinical development and are not yet sold.